Real-World study shows Tucatinib's impact on advanced breast cancer
NCT ID NCT05253911
First seen Jan 11, 2026 · Last updated May 16, 2026 · Updated 11 times
Summary
This study looked at how well the drug tucatinib works in everyday medical practice for people with advanced HER2-positive breast cancer who have already tried at least two other treatments. Researchers tracked 49 adults in Germany and Austria to see how their quality of life changed and how long it took for their cancer to progress. The goal was to understand the real-world benefits of adding tucatinib to standard therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medizinische Universität Wien, Innere Medizin I, Hämatologie und Onkologie
Vienna, 1090, Austria
-
Universitätsklinikum Essen, Innere Klinik (Tumorforschung)
Essen, North Rhine-Westphalia, D-45112, Germany
Conditions
Explore the condition pages connected to this study.